Open Access

Mitochondrial dynamics and biogenesis indicators may serve as potential biomarkers for diagnosis of myasthenia gravis

  • Authors:
    • Lanqi Li
    • Donghong Cai
    • Huiya Zhong
    • Fengbin Liu
    • Qilong Jiang
    • Jian Liang
    • Peiwu Li
    • Yafang Song
    • Aidong Ji
    • Wei Jiao
    • Jingwei Song
    • Jinqiu Li
    • Zhiwei Chen
    • Qing Li
    • Lingling Ke
  • View Affiliations

  • Published online on: February 24, 2022     https://doi.org/10.3892/etm.2022.11236
  • Article Number: 307
  • Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Due to challenges in diagnosing myasthenia gravis (MG), identifying novel diagnostic biomarkers for this disease is essential. Mitochondria are key organelles that regulate multiple physiological functions, such as energy production, cell proliferation and cell death. In the present study, Mfn1/2, Opa1, Drp1, Fis1, AMPK, PGC‑1α, NRF‑1 and TFAM were compared between patients with MG and healthy subjects to identify potential diagnostic biomarkers for MG. Blood samples were collected from 50 patients with MG and 50 healthy subjects. The participants' demographic information and routine blood test results were recorded. Mitochondrial dynamics were evaluated and levels of Mfn1/2, Opa1, Drp1, Fis1, AMPK, PGC‑1α, NRF‑1 and TFAM were determined in peripheral blood mononuclear cells using western blotting and reverse transcription‑quantitative PCR, respectively. Receiver operating characteristic curve analysis was used to evaluate the diagnostic accuracy of these indicators. The areas under the curve values of Mfn1/2, Opa1, Drp1, Fis1,AMPK, PGC‑1α, NRF‑1 and TFAM were 0.5408‑0.8696. Compared with control subjects, mRNA expression levels of Mfn1/2, Opa1, AMPK, PGC‑1α, NRF‑1 and TFAM were lower, while those of Drp1 and Fis1 were higher in patients with MG. The protein expression levels of all these molecules were lower in patients with MG than in control subjects. These results suggested that mitochondrial dynamics and biogenesis indicators may be diagnostic biomarkers for MG.
View Figures
View References

Related Articles

Journal Cover

April-2022
Volume 23 Issue 4

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Li L, Cai D, Zhong H, Liu F, Jiang Q, Liang J, Li P, Song Y, Ji A, Jiao W, Jiao W, et al: Mitochondrial dynamics and biogenesis indicators may serve as potential biomarkers for diagnosis of myasthenia gravis. Exp Ther Med 23: 307, 2022
APA
Li, L., Cai, D., Zhong, H., Liu, F., Jiang, Q., Liang, J. ... Ke, L. (2022). Mitochondrial dynamics and biogenesis indicators may serve as potential biomarkers for diagnosis of myasthenia gravis. Experimental and Therapeutic Medicine, 23, 307. https://doi.org/10.3892/etm.2022.11236
MLA
Li, L., Cai, D., Zhong, H., Liu, F., Jiang, Q., Liang, J., Li, P., Song, Y., Ji, A., Jiao, W., Song, J., Li, J., Chen, Z., Li, Q., Ke, L."Mitochondrial dynamics and biogenesis indicators may serve as potential biomarkers for diagnosis of myasthenia gravis". Experimental and Therapeutic Medicine 23.4 (2022): 307.
Chicago
Li, L., Cai, D., Zhong, H., Liu, F., Jiang, Q., Liang, J., Li, P., Song, Y., Ji, A., Jiao, W., Song, J., Li, J., Chen, Z., Li, Q., Ke, L."Mitochondrial dynamics and biogenesis indicators may serve as potential biomarkers for diagnosis of myasthenia gravis". Experimental and Therapeutic Medicine 23, no. 4 (2022): 307. https://doi.org/10.3892/etm.2022.11236